P2RY12 and atrial fibrillation: Apixaban showed similar ischemic outcomes to warfarin with lessdeath or hospitalization composite events (HR 0.83; 95% CI: 0.74–0.93) [53].The SAFE-A (SAFety and Effectiveness trial of Apixaban use in association withdual antiplatelet therapy in patients with atrial fibrillation undergoingpercutaneous coronary intervention) randomized controlled trial evaluated thewithdrawal of P2Y12 inhibitors from triple antithrombotic therapy after oneor six months of therapy in AF patients undergoing PCI.